ASLNASLAN Pharmaceuticals Ltd

Nasdaq www.aslanpharma.com


$ 2.28 $ 0.13 (5.87 %)    

Wednesday, 03-Jul-2024 11:49:26 EDT
QQQ $ 490.95 $ 4.06 (0.83 %)
DIA $ 392.84 $ -0.46 (-0.12 %)
SPY $ 551.46 $ 2.45 (0.45 %)
TLT $ 91.86 $ 1.19 (1.31 %)
GLD $ 217.99 $ 2.43 (1.13 %)
$ 2.38
$ 2.44
$ 0.00 x 0
$ 0.00 x 0
$ 2.27 - $ 2.44
$ 2.17 - $ 30.77
56,699
na
36.33M
$ 1.68
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aslan-pharmaceuticals-announces-plan-to-implement-ads-ratio-change-from-1-ads-representing-25-shares-to-1-ads-representing-200-shares-1-for-8-ads-split-effective-date-for-the-ratio-change-july-3-2024

ASLAN Pharmaceuticals (("ASLAN" or the "Company", NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmac...

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-announces-expansion-of-its-collaboration-with-zenyaku-to-investigate-the-biology-underlying-differential-effects-of-eblasakimab-compared-to-other-biologics

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies ...

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 aslan-pharmaceuticals-reports-interim-results-from-phase-2-study-of-eblasakimab-in-dupilumab-experienced-atopic-dermatitis-patients

https://www.sec.gov/Archives/edgar/data/1722926/000095017024046201/asln-ex99_1.htm 

 hc-wainwright--co-reiterates-buy-on-aslan-pharma-maintains-9-price-target

HC Wainwright & Co. analyst Yi Chen reiterates ASLAN Pharma (NASDAQ:ASLN) with a Buy and maintains $9 price target.

 hc-wainwright--co-maintains-buy-on-aslan-pharma-lowers-price-target-to-9

HC Wainwright & Co. analyst Yi Chen maintains ASLAN Pharma (NASDAQ:ASLN) with a Buy and lowers the price target from $17...

 piper-sandler-reiterates-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff reiterates ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fr...

 piper-sandler-maintains-overweight-on-aslan-pharma-lowers-price-target-to-10

Piper Sandler analyst Edward Tenthoff maintains ASLAN Pharma (NASDAQ:ASLN) with a Overweight and lowers the price target fro...